3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
75
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
5
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Metastatic Castration-Resistant Prostate Cancer
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
Breast Neoplasms
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Solid Tumours
1
Salivary Gland Neoplasms
1
Prostatic Diseases
1
Prostate Cancer Metastatic Disease
1
Interventions
Fluorouracil
26
Radiotherapy
17
Mitomycin
17
Cisplatin
12
Capecitabine
12
pembrolizumab
10
Cyclophosphamide
9
Radiation
8
Paclitaxel
8
fludarabine
7
Specimen Handling
7
Nivolumab
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Cetuximab
6
Biopsy
6
Papillomavirus Vaccines
5
Drug Therapy
5
dehydroftorafur
4
aldesleukin
4
Vaccines
4
Radiotherapy, Intensity-Modulated
4
Irinotecan
4
Watchful Waiting
3
Taxes
3
Oxaliplatin
3
Observation
3
Light Coagulation
3
Ipilimumab
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Anus Neoplasms
×
abiraterone
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts